Jardiance Cost in Georgia 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is the Actual Cash Price of Jardiance in Georgia in 2026?

The brand-name Jardiance list price in Georgia is approximately $680 per month for a 30-tablet supply in 2026, consistent with the national Boehringer Ingelheim / Eli Lilly manufacturer list price. Without insurance or a savings program, most Georgia retail pharmacies charge close to that figure. GoodRx coupons can reduce the price at chains such as CVS, Walgreens, and Kroger Pharmacy to a range of $550 to $650 depending on the specific location and current coupon availability, but that still leaves empagliflozin as one of the more expensive oral medications in its class.

Cost-per-day at list price works out to roughly $22. For patients paying entirely out of pocket, that annual burden exceeds $8,100. The SGLT2 inhibitor class as a whole carries similar pricing: dapagliflozin (Farxiga) and canagliflozin (Invokana) sit in the same $600 to $700 monthly range at list price [1].

The FDA approved empagliflozin under NDA 204629; the current prescribing information confirms the 10 mg and 25 mg tablet strengths used in all cost calculations below [2]. Georgia's state average drug prices track closely with national averages because Georgia has no state-level drug price negotiation law comparable to those in Maryland or California.

One practical note: prices vary by pharmacy. Costco and Sam's Club pharmacies in Atlanta, Savannah, and Augusta frequently post lower cash prices than chain drugstores, sometimes 8 to 12 percent below the CVS or Walgreens cash price for the same 30-day supply [3].

Does Georgia Medicaid Cover Jardiance?

Georgia Medicaid (administered through Georgia Families managed care plans) covers empagliflozin for heart failure and chronic kidney disease (CKD) indications but does not cover it as a first-line or routine add-on agent for type 2 diabetes alone as of 2026. Prescribers must submit prior authorization documentation for covered indications. The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors for patients with type 2 diabetes who also have established cardiovascular disease, heart failure, or CKD, regardless of HbA1c [4]. That clinical framing is what Georgia Medicaid managed care plans use to justify coverage in those comorbid populations.

For a Georgia Medicaid patient who has heart failure with reduced ejection fraction, the EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% vs. placebo (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [5]. That level of evidence supports the cardiologist or primary care physician documenting the heart failure diagnosis clearly so the Medicaid prior authorization goes through.

Patients on Georgia Medicaid for type 2 diabetes without those comorbidities are typically steered toward metformin, sulfonylureas, or older formulary agents. If your prescriber believes empagliflozin is medically necessary for glycemic control alone, they can file an exception request, but approval rates for that pathway are low in Georgia's managed care environment [6].

Georgia PeachCare for Kids does not cover empagliflozin; the drug is approved only for adults age 18 and older [2].

Which Georgia Insurance Plans Cover Jardiance?

Most commercial plans sold on the Georgia ACA marketplace, employer-sponsored plans, and Medicare Part D plans cover Jardiance, though tier placement varies. The majority of plans place empagliflozin on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), producing copays between $45 and $120 per month after the deductible is met [7].

Medicare Part D enrollees face a different cost structure. Under the Inflation Reduction Act's redesigned Part D benefit effective 2025, out-of-pocket costs for all Part D drugs are capped at $2,000 per year [8]. For empagliflozin, that cap is meaningful because patients previously spent several hundred dollars monthly in the coverage gap. Georgia Medicare Advantage plans from Humana, UnitedHealthcare, and Aetna each maintain their own formularies; some place empagliflozin on Tier 2 with $47 copays while others place it on Tier 4 with 25 to 33 percent coinsurance [9].

Employer self-insured plans in Georgia are governed by ERISA and are not required to follow Georgia state insurance mandates. Many large Georgia employers (including those in the logistics, healthcare, and financial sectors concentrated in Atlanta) cover empagliflozin but impose step-therapy requirements, meaning patients must try and fail metformin plus one other agent before Jardiance is approved [10].

The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Management Algorithm explicitly states that SGLT2 inhibitors should be preferred agents in patients with atherosclerotic cardiovascular disease or CKD, which gives prescribers guideline-backed ammunition when appealing a step-therapy denial [11].

How Does the Boehringer Ingelheim / Lilly Jardiance Savings Card Work in Georgia?

Boehringer Ingelheim and Eli Lilly jointly market Jardiance and offer a co-pay savings card through their patient assistance infrastructure. Commercially insured Georgia residents who are not enrolled in any federal or state government health program (Medicare, Medicaid, TRICARE, or VA) may pay as little as $10 per month using the Jardiance Savings Card [12].

The card has a maximum annual benefit of $3,600, which effectively covers 12 months of co-pays up to $300 each. Patients enroll at JardiancePro.com or through a HealthRX-affiliated telehealth provider who can activate the enrollment during the prescribing visit. The savings card is accepted at virtually every retail pharmacy in Georgia, including independent pharmacies in rural counties where Jardiance is stocked [12].

Patients who are uninsured do not qualify for the $10/month savings card rate. They are instead directed to the Lilly Cares Foundation or the Boehringer Ingelheim Cares Foundation patient assistance programs, which can provide Jardiance at no cost for patients who meet income eligibility thresholds (generally at or below 400% of the federal poverty level) [13].

The NeedyMeds database and RxAssist both list Georgia-specific eligibility pathways for these foundation programs. Processing time after application is typically 3 to 6 weeks, so patients should not delay applying if cost is a barrier [14].

Is Compounded Empagliflozin Legal in Georgia?

Compounded empagliflozin is legal in Georgia when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. The FDA defines 503A pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act; these are traditional compounding pharmacies that may prepare customized drug preparations for individual patients [15]. Georgia's pharmacy practice is regulated by the Georgia State Board of Pharmacy, which permits 503A compounding of drug substances that are not on the FDA-prohibited list. Empagliflozin is not currently on that list [16].

Compounded empagliflozin preparations are typically oral capsules in doses ranging from 10 mg to 25 mg. The active pharmaceutical ingredient (API) used must be sourced from an FDA-registered API manufacturer. Pricing through compounding pharmacies in Georgia or through telehealth-affiliated compounding pharmacies ranges widely, with some programs offering compounded empagliflozin at dramatically lower cost than the $680 brand-name price, sometimes at $60 to $150 per month depending on the pharmacy and formulation [17].

One important distinction: 503B outsourcing facilities (which produce compounded drugs in bulk without individual prescriptions) may also supply Georgia-licensed pharmacies, but they operate under stricter FDA oversight. The FDA's current shortage and compounding policies for SGLT2 inhibitors continue to evolve; patients and prescribers should verify current status before initiating a compounded regimen [15].

Compounded empagliflozin is not FDA-approved and has not undergone the same bioavailability and stability testing as the brand-name product. A 2023 analysis in the Journal of Clinical Pharmacology noted that SGLT2 inhibitor compounded preparations showed variable dissolution profiles compared to reference-listed drugs, which could affect clinical outcomes [18]. Patients considering this option should discuss the trade-off with their prescriber.

What Clinical Evidence Justifies the Cost of Empagliflozin?

The price of Jardiance can be hard to accept until you look at the outcomes data. EMPA-REG OUTCOME (N=7,020), published in the New England Journal of Medicine in 2015, found that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% vs. placebo (HR 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority, P=0.04 for superiority) in adults with type 2 diabetes and established cardiovascular disease [19]. Cardiovascular death alone fell by 38% (HR 0.62 to 95% CI 0.49 to 0.77).

The EMPEROR-Preserved trial (N=5,988), published in the New England Journal of Medicine in 2021, extended empagliflozin's indication to heart failure with preserved ejection fraction (HFpEF), showing a 21% reduction in the primary outcome of cardiovascular death or heart failure hospitalization (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001) [20].

For CKD, the EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001), leading to FDA approval for CKD in 2023 [21].

The ADA 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, SGLT2 inhibitors with proven cardiovascular benefit are recommended as part of the glucose-lowering regimen independent of baseline HbA1c or individualized HbA1c target" [4]. That guideline language matters directly for Georgia Medicaid prior authorization letters.

For HbA1c reduction, empagliflozin 10 mg lowers HbA1c by approximately 0.6 to 0.8 percentage points as monotherapy and 0.5 to 0.7 percentage points added to metformin in 24-week trials [2]. Body weight falls by 2 to 3 kg at 24 weeks, and systolic blood pressure drops roughly 3 to 4 mmHg, effects documented across multiple registration trials included in the FDA label [2].

How to Get the Cheapest Possible Empagliflozin in Georgia: A Decision Framework

The right cost-reduction path depends on your insurance status. Work through these tiers in order.

Tier 1: Commercially insured patients. Activate the Boehringer Ingelheim / Lilly savings card immediately. Your cost drops to $10/month. No further action needed unless your plan requires prior authorization, in which case your prescriber should reference EMPA-REG OUTCOME and the ADA 2024 guideline language above [4, 19].

Tier 2: Georgia Medicaid patients. If you have heart failure or CKD, your prescriber must document the diagnosis with ICD-10 codes I50.x (heart failure) or N18.x (CKD stage 3 to 5) on the prior authorization form. Citing EMPEROR-Reduced [5] or EMPA-KIDNEY [21] in the clinical justification section improves approval rates. For type 2 diabetes alone, file an exception request citing documented cardiovascular risk.

Tier 3: Medicare Part D patients. Confirm your plan's tier placement during open enrollment (October 15 to December 7 each year). If Jardiance is on Tier 4 or 5, ask your prescriber to request a formulary exception citing Medicare's requirement to cover medically necessary drugs. The $2,000 annual out-of-pocket cap under the 2025 Part D redesign provides a ceiling on total exposure [8].

Tier 4: Uninsured patients. Apply to the Lilly Cares Foundation or the Boehringer Ingelheim Cares Foundation for free drug. Simultaneously, ask your HealthRX provider whether compounded empagliflozin from a licensed Georgia 503A pharmacy is clinically appropriate for your situation [13, 15].

Tier 5: Patients in rural Georgia with limited pharmacy access. Telehealth prescribing is legal in Georgia [22]. HealthRX providers can send prescriptions to mail-order pharmacies including Express Scripts, CVS Caremark, and OptumRx, or to compounding pharmacies that ship within Georgia. Mail-order 90-day supplies typically cost 10 to 15 percent less per tablet than 30-day retail supplies when covered by insurance [23].

Dosing, Administration, and Monitoring in Georgia Patients

Empagliflozin is taken once daily in the morning, with or without food. The standard starting dose is 10 mg. For additional glycemic control, the dose may be increased to 25 mg once daily. For heart failure and CKD indications, 10 mg once daily is the target dose; the 25 mg dose does not add benefit in those populations [2].

Before starting empagliflozin, clinicians should check eGFR. The drug is not recommended for initiation if eGFR is <30 mL/min/1.73 m2, and glycemic efficacy diminishes at eGFR <45 mL/min/1.73 m2 [2]. The FDA label cautions against use in patients with recurrent urinary tract infections, and patients should be counseled about the risk of genital mycotic infections, which occur in roughly 6 to 7% of women and 3 to 4% of men in registration trials [2].

Euglycemic diabetic ketoacidosis (DKA) is a rare but serious risk, particularly in patients who are fasting, severely ill, or undergoing surgery. The FDA issued a safety communication on this risk in 2015; patients and providers should be aware of it [24]. The ADA recommends holding SGLT2 inhibitors at least 3 to 4 days before elective surgery [4].

Monitoring parameters in Georgia primary care and endocrinology practice typically include HbA1c every 3 months until stable, then every 6 months; eGFR and serum potassium at baseline and annually; and blood pressure at each visit given the drug's modest antihypertensive effect [11].

Telehealth Access to Jardiance in Georgia

Georgia law permits telehealth prescribing of Schedule-unscheduled medications including empagliflozin. The Georgia Composite Medical Board and Georgia Board of Pharmacy both permit prescribing via synchronous audio-video encounters, and some platforms additionally accept asynchronous (store-and-forward) encounters for established patients [22].

A HealthRX telehealth visit for empagliflozin typically includes a review of your HbA1c, eGFR, cardiovascular history, and current medication list. The visit takes roughly 15 to 25 minutes. The prescriber can send the prescription directly to your preferred Georgia pharmacy or to a mail-order pharmacy. Savings card activation and prior authorization paperwork can be completed the same day through HealthRX's administrative support team.

The Centers for Medicare and Medicaid Services confirmed in its 2024 telehealth policy update that telehealth-initiated prescriptions for non-controlled substances carry the same insurance validity as in-person prescriptions [25]. Georgia Medicaid similarly recognizes telehealth-initiated prescriptions for covered medications under its current managed care contracts [6].

Empagliflozin vs. Other SGLT2 Inhibitors in Georgia: Cost Comparison

Georgia patients sometimes ask whether dapagliflozin (Farxiga) or canagliflozin (Invokana) would be cheaper. All three carry similar list prices near $650 to $700 per month in 2026. AstraZeneca offers a similar savings card for Farxiga; Janssen does so for Invokana. The clinical differentiation matters more than modest price differences for most patients.

Empagliflozin has the most extensive cardiovascular mortality data (EMPA-REG OUTCOME, 38% relative reduction in cardiovascular death [19]). Dapagliflozin's DECLARE-TIMI 58 trial (N=17,160) showed noninferiority for major adverse cardiovascular events but did not show a mortality benefit in the overall population [26]. Canagliflozin's CANVAS Program showed cardiovascular benefit but a higher rate of lower-limb amputations (HR 1.97 to 95% CI 1.41 to 2.75) that led to an FDA black box warning [27]. For most Georgia prescribers managing patients with established cardiovascular disease, empagliflozin or dapagliflozin are preferred based on their respective outcome data.

If your Georgia insurer covers Farxiga at a lower tier than Jardiance, the clinical profiles are similar enough that switching may be reasonable. Discuss formulary-driven substitution with your prescriber and confirm that your specific indication (T2D, HF, or CKD) is covered under the alternative drug's FDA labeling [2, 28].